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A B S T R A C T
Acinetobacter calcoaceticus–baumannii complex is a common cause of hospital-acquired infections (HAIs)
globally, remarkable for its high rate of antibiotic resistance, including to carbapenems. There are few
data on the resistance of A. baumannii in Vietnam, which are essential for developing evidence-based
treatment guidelines for HAIs. Antibiotic susceptibility testing was conducted by VITEK12, and pulsed-
ﬁeld gel electrophoresis (PFGE) was performed on 66 clinical A. baumannii complex isolates recovered
during 2009 at the National Hospital of Tropical Diseases (NHTD), a referral hospital in Hanoi, Vietnam.
Basic demographic and clinical data were collected and analysed using descriptive statistics. Most
isolates came from lower respiratory tract specimens (59; 89.4%) from intensive care unit (ICU) patients
[64/65 (98.5%) with available data] who had been admitted to NHTD for 2 days [42/46 (91.3%) with
available data]. More than 90% of the isolates were resistant to the tested b-lactamase/b-lactamase
inhibitors, cephalosporins, carbapenems, ﬂuoroquinolones and trimethoprim/sulfamethoxazole.
Moreover, 25.4% (16/63) were resistant to all tested b-lactams, quinolones and aminoglycosides. All
isolates remained sensitive to colistin and 58.7% were susceptible to tigecycline. Of the 66 isolates, 49
could be classiﬁed into eight PFGE types (A–H). Every PFGE type, except D, had cluster(s) of three or more
isolates with a temporal relationship. In conclusion, these data suggest a signiﬁcant rise in A. baumannii
antibiotic resistance in Vietnam. Clustering within PFGE types supports cross-transmission of A.
baumannii within the ICU at NHTD. Increased research and resources in optimising treatment, infection
control and antibiotic stewardship are needed.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Chemotherapy of
Infection and Cancer. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/3.0/).
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Acinetobacter calcoaceticus–baumannii complex is emerging as
one of the most common causes of hospital-acquired infections
(HAIs) in intensive care units (ICUs) worldwide and is often
resistant to multiple antibiotic classes, complicating treatment [1].* Corresponding author. Present address: Oxford University Clinical Research
Unit, National Hospital of Tropical Diseases, 78 Giai Phong Street, Hanoi, Viet Nam.
Tel.: +84 43576 4320; fax: +84 43576 4319.
E-mail address: queenie.dinh@gmail.com (Q.-D. Dinh).
1 These two authors contributed equally to this work.
http://dx.doi.org/10.1016/j.jgar.2014.05.003
2213-7165/ 2014 The Authors. Published by Elsevier Ltd on behalf of International Socie
CC BY license (http://creativecommons.org/licenses/by/3.0/).Acinetobacter baumannii is a strictly aerobic, non-motile, Gram-
negative bacillus belonging to the A. calcoaceticus–baumannii
complex within the family Moraxellaceae of the order Gamma-
proteobacteria. Identiﬁcation by phenotypic methods or DNA–
DNA hybridisation does not reliably distinguish A. baumannii
from other members of the A. calcoaceticus–baumannii complex
(henceforth referred to as A. baumannii) [1]. This poses
challenges clinically because A. baumannii can be pathogenic
whereas A. calcoaceticus is environmental. The exact reservoir of
A. baumannii remains undeﬁned [2]. In contrast to other
Acinetobacter spp., A. baumannii is uncommon in nature
compared with the hospital environment [1]. A. baumannii isty for Chemotherapy of Infection and Cancer. This is an open access article under the
Table 1
Antibiotic susceptibility testing of 63 Acinetobacter baumannii isolates at the
National Hospital of Tropical Diseases (Hanoi, Vietnam), 2009.
Antibiotic Susceptible Intermediate Resistant
% n % n % n
AMC 0.0 0 0.0 0 100.0 63
TZP 1.6 1 3.2 2 95.2 60
Cefotaxime 0.0 0 1.6 1 98.4 62
Ceftazidime 0.0 0 1.6 1 98.4 62
Cefepime 0.0 0 1.6 1 98.4 62
Imipenem 7.9 5 0.0 0 92.1 58
Meropenem 7.9 5 0.0 0 92.1 58
Gentamicin 17.5 11 27.0 17 55.6 35
Tobramycin 31.7 20 25.4 16 42.9 27
Ciproﬂoxacin 1.6 1 0.0 0 98.4 62
Levoﬂoxacin 1.6 1 7.9 5 90.5 57
Tigecycline 58.7 37 38.1 24 3.2 2
Colistin 100.0 63 0.0 0 0.0 0
SXT 0.0 0 0.0 0 100.0 63
AMC, amoxicillin/clavulanic acid; TZP, piperacillin/tazobactam; SXT, trimethoprim/
sulfamethoxazole.
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to 4 months [3].
A. baumannii infection occurs when the immunological
barriers of the host are breached (e.g. mechanical ventilation)
and is hence considered an opportunistic pathogen [4]. A.
baumannii causes various types of HAI, including ventilator-
associated pneumonia (VAP), bacteraemia, urinary tract infection,
meningitis, and infections complicating burn wounds [5].
Treatment is difﬁcult due to the high rates of antibiotic resistance
worldwide, including resistance to carbapenems [2]. However,
few data are available on the molecular epidemiology and
antibiotic resistance of A. baumannii infections in Asia, including
Vietnam. Rapid development in Vietnam has been accompanied
by the increasing availability of complex healthcare, including
ICUs, and accompanied by HAIs. As the isolation of A. baumannii is
reported to be particularly common in VAP, it is crucial to
know more regarding the resistance and epidemiology of these
bacteria in a resource-constrained setting such as Vietnam. This
study describes the antibiotic susceptibility and molecular
epidemiology of A. baumannii isolates from a referral hospital
in Hanoi, Vietnam.
2. Materials and methods
2.1. Design
This was a retrospective study examining the molecular
epidemiology and antibiotic susceptibility of clinical A. baumannii
isolates collected from hospitalised patients from January to
December 2009 at the National Hospital for Tropical Diseases
(NHTD) in Hanoi. The NHTD is a tertiary referral hospital for adult
infectious diseases with a catchment area that covers Hanoi and
the surrounding northern provinces. At the time of the study,
NHTD had 150 inpatient beds including 15 ICU beds, and ca. 4000
inpatient admissions annually. The study was approved by the
Scientiﬁc and Ethical Committee of NHTD.
2.2. Isolates
In this study, 66 stored A. baumannii isolates cultured from
unique patients admitted to NHTD in 2009 were viable and
available for study, from a total of 99 A. baumannii isolates. For
each patient, the ﬁrst isolate was selected and isolates from sterile
sites were chosen over respiratory samples, whenever possible. A.
baumannii isolates were identiﬁed by standard microbiological
methods, including API 20 NE (bioMe´rieux, Marcy-l’E´toile,
France). PCR targeting the blaOXA-51-like gene was conducted later
and was positive in 48 of the 48 available isolates [6]. Isolates were
stored in glycerol medium at 70 8C. In total, 63 isolates were
subjected to antibiotic susceptibility testing according to Clinical
and Laboratory Standards Institute (CLSI) guidelines using the
VITEK12 system with card AST-N089 22237 (bioMe´rieux) for the
following antibiotics: ampicillin; amoxicillin/clavulanic acid;
piperacillin/tazobactam; ceftazidime; cefotaxime; cefepime;
imipenem; meropenem; amikacin; gentamicin; tobramycin;
ciproﬂoxacin; levoﬂoxacin; trimethoprim/sulfamethoxazole
(SXT); colistin; and tigecycline. This antibiotic card interprets
tigecycline susceptibility according to US Food and Drug
Administration (FDA) breakpoints for Enterobacteriaceae. In
total, 58 isolates were typed by pulsed-ﬁeld gel electrophoresis
(PFGE) as previously described using the restriction enzyme ApaI
[7,8]. In addition, data were collected on specimen source and date
of collection. From the patient chart, data were collected on
patient demographics, location, and brief clinical data such as type
of infection.2.3. Analysis
Susceptibility data were analysed using WHOnet 5.5 software
(World Health Organization, Geneva, Switzerland). Amikacin data
are not shown as these are considered to be unreliable when tested
by the VITEK system [9]. Analysis of PFGE results was done visually
using the criteria of Tenover et al. [10] by two readers (VDT and
HW) and discrepancies were resolved by a third reader (QD).
Isolates with PFGE patterns that were indistinguishable (zero
genetic differences) or closely related (one genetic difference) were
grouped together. Isolate and patient data were analysed using
Microsoft Excel 2010 (Microsoft Corp., Redmond, WA) using
descriptive statistics as appropriate.
3. Results
3.1. Source of the A. baumannii isolates
The 66 A. baumannii isolates came from the lower respiratory
tract (59; 89.4%), blood (6; 9.1%) and pus (1; 1.5%). The median
patient age was 51 years (range 17–93 years) and the majority of
patients were male (48; 72.7%). The 59 A. baumannii isolates from
sputum comprised 13.1% of a total of 451 sputum specimens.
Almost all patients were admitted to the ICU (64/65 with available
data). The reason(s) for ICU admission was available for 43 patients
(some patients had more than one reason for ICU admission listed)
and included pneumonia in 14 (32.6%), sepsis or septic shock in 10
(23.3%), tetanus in 9 (20.9%), central nervous system infection in 8
(18.6%), and substance abuse, respiratory failure not otherwise
speciﬁed, dengue fever, and fever not otherwise speciﬁed each in 2
patients (4.7%). Most specimens were collected for clinical
suspicion of VAP. Most specimens were collected 2 days after
the patient’s admission to NHTD [42/46 (91.3%) where dates of
admission and specimen collection were both available] and were
therefore compatible with HAI. Patient information for three of the
remaining specimens indicated that the patients had been
transferred from another hospital; however, the length of stay
at the referring hospital was not available.
3.2. Antibiotic susceptibility
In total, 63 isolates underwent antibiotic susceptibility testing
using the VITEK12 system (Table 1). Resistance rates were
high, with >90% of isolates being resistant to the tested
b-lactamase/b-lactamase inhibitors, cephalosporins, carbapenems,
Fig. 1. Clustering of Acinetobacter calcoaceticus–baumannii complex isolates in 2009
at the National Hospital of Tropical Diseases (Hanoi, Vietnam) within pulsed-ﬁeld
gel electrophoresis (PFGE) types A–C and E–H. * Indicates cluster isolates.
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to both gentamicin and tobramycin, and 25.4% of isolates (n = 16)
were resistant to all tested b-lactams, quinolones and aminoglyco-
sides. All isolates remained sensitive to colistin and 58.7% were
susceptible to tigecycline.
3.3. Pulsed-ﬁeld gel electrophoresis
Of the 58 isolates that underwent PFGE, 49 were classiﬁed into
eight PFGE types and were assigned the letters A–H (Supplemen-
tary Fig. S1). The letter assignment is not intended to ascribe
relatedness among the PFGE types. PFGE type A isolates (n = 6)
originated from sputum, type B (n = 7) from sputum (4) and blood
(3), type C (n = 15) from sputum (14) and blood (1), and types D
(n = 3), E (n = 4), F (n = 4), G (n = 5) and H (n = 5) were all from
sputum. The remaining nine isolates, including two blood isolates,
did not appear related to other isolates by PFGE.
Supplementary Fig. I related to this article can be found, in the
online version, at doi:10.1016/j.jgar.2014.05.003.
Every PFGE type, except D type, had cluster(s) of three or more
isolates that were temporally related, with time spans ranging
from 6 days to 67 days (Fig. 1). On average, isolates within each
cluster were detected every 2–16.8 days. Type A isolates, which
clustered in May and October, had identical antibiotic testing
results, with susceptibility only to tigecycline and colistin
(Table 2). Isolates within the other PFGE types differed in antibiotic
resistance by at least one antibiotic class, most often the
aminoglycosides, but also the carbapenems, quinolones and
tigecycline. The type B and C clusters included all the blood
isolates from those types.Table 2
Antibiotic susceptibility patternsa according to pulsed-ﬁeld gel electrophoresis (PFGE) 
Antibiotic/antibiotic class PFGE type
A (6) Bb (7) C (15
b-Lactamase/b-lactamase inhibitors R R R 
Cephalosporins R R R 
Carbapenems R r/s R 
Gentamicin R r/i/s r/i 
Tobramycin R r/s r/i/s 
Fluoroquinolones R R R 
Tigecycline S S I 
Colistin S S S 
SXT R R R 
R, resistant; I, intermediate; S, susceptible; SXT, trimethoprim/sulfamethoxazole.
a Susceptibility phenotypes reported in non-capitalised letters and separated by a sl
b Antibiotic testing data were missing for one isolate.4. Discussion and conclusion
This study presents antibiotic susceptibility data for 63 A.
baumannii isolates at a referral hospital in Hanoi, Vietnam, in 2009.
The majority of isolates came from sputum samples collected from
ICU patients 2 days into their admission at NHTD. There were
high rates of resistance, including nearly complete resistance to all
tested b-lactam antibiotics. Susceptibility to colistin and tigecy-
cline remained high. The VITEK 2 system used in this study is
considered reliable for most antibiotics, including colistin [11].
Amikacin was excluded from this analysis as testing for amikacin
susceptibility by VITEK 2 was previously shown to produce very
major errors more than one-third of the time compared with broth
microdilution [9].
Data from northern Vietnam on A. baumannii isolates from 1997
to 1998 showed considerably less resistance, with resistance rates
of ca. 50% for cephalosporins, 50% for aminoglycosides, 25% for
quinolones and 50% for SXT (Dr. Ðoa`n Mai Phu’o’ng, Bach Mai
Hospital, Vietnam, unpublished data). These data suggest a sharp
increase in A. baumannii resistance over the last 10 years in
Vietnam. This is supported by the COMPACT II study, which
reported 89.5% carbapenem-non-susceptibility by Etest among 19
A. baumannii isolates from Vietnam, comparable with the current
results [12]. In a recent study at a hospital in western China, 31 A.
baumannii isolates from the ICU were also highly resistant,
including 96.3% to SXT, 92.6% to cefotaxime and 55.6% to
carbapenems [13].
These results raise questions regarding what constitutes
appropriate empirical and deﬁnitive treatment of highly resistant
A. baumannii infections, including the use of combination therapy
and colistin. In this study, rifampicin was not tested, which is
active alone and in combination in in vitro and animal studies
[14,15]. However, clinical data on the use of rifampicin in
combination has generally been non-comparative. At NHTD,
testing amikacin susceptibility using a more reliable method
may broaden the available therapeutic options. Meanwhile, there
is increasing reliance on colistin, even though it is not always
readily available in Vietnam and is relatively costly. A global
colistin usage survey indicated that in Vietnam, no loading dose of
colistin is given, which may lead to treatment failure [16]. In
general, underdosing of colistin risks the development of bacterial
resistance against this last-line drug (unpublished data).
Numerous PFGE types were identiﬁed, suggesting a diverse
population of A. baumannii rather than the spread of a speciﬁc
clone. Nevertheless, PFGE types C and H appeared dominant,
clustering from October to December and January to February,
respectively. Conﬁdence in the smaller clusters was limited by the
sample size. The clonality of these PFGE types is supported by
similarities in antibiotic susceptibility proﬁles. The clusterstype.
) D (3) E (4) F (4) Gb (5) H (5)
R R R R R
R R R R R
R R R R R
R R R r/i/s r/i
i/s R r/i r/s i/s
R r/i R R R
i/s i/s S S r/i/s
S S S S S
R R R R R
ash indicate varying susceptibility patterns within that cluster of strains.
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types in 2009 and emphasise the importance of rigorous infection
control.
This study has limitations that need to be acknowledged.
Limitations in microbiological and clinical data could have led to
the inclusion of isolates from specimens that represented
colonisation and contamination rather than infection. We also
did not have details on where patients were located within the ICU
to prove environmental, healthcare worker, or direct patient-to-
patient spread of infection. Furthermore, we did not distinguish
between pathogenic A. baumannii species from the environmental
species A. calcoaceticus. A signiﬁcant number of isolates were either
not viable or were not groupable by PFGE, limiting the detection of
PFGE types and clusters. However, we do not expect any selection
bias in the isolates tested, which do provide us important
information on the resistance patterns of A. calcoaceticus–
baumannii complex strains in Vietnam.
These data show that A. calcoaceticus–baumannii complex is an
important cause of HAIs in ICUs in northern Vietnam. The high rates
of antibiotic resistance present a major opportunity for conducting
treatment trials to determine the optimal treatment of A. baumannii
HAIs, including the best timing and dosing of colistin as well as the
role of combination therapy. Given the temporal clustering of
related A. baumannii types, adequate resources need to be dedicated
towards antibiotic stewardship and infection control activities. We
are undertaking further studies on VAP and a nationwide HAI
surveillance programme, which will inform future steps.
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